NRXP NRX Pharmaceuticals Inc

Price (delayed)

$2.06

Market cap

$19.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4

Enterprise value

$24.28M

Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination ...

Highlights

NRXP's EPS is up by 33% year-on-year and by 20% since the previous quarter

NRX Pharmaceuticals's net income has increased by 24% YoY and by 16% from the previous quarter

The company's equity has shrunk by 89% QoQ

NRX Pharmaceuticals's quick ratio has plunged by 81% YoY and by 48% from the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.bigrockpartners.com/spac/spac_aboutus.html

Peers: OMER OMGA

Key stats

What are the main financial stats of NRXP

Market

Shares outstanding

9.57M

Market cap

$19.71M

Enterprise value

$24.28M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$30.03M

EBITDA

-$30.03M

Free cash flow

-$21.66M

Per share

EPS

-$4

Free cash flow per share

-$2.86

Book value per share

-$1.4

Revenue per share

TBVPS

$0.97

Balance sheet

Total assets

$7.32M

Total liabilities

$19.05M

Debt

$9.16M

Equity

-$11.73M

Working capital

-$12.16M

Liquidity

Debt to equity

-0.78

Current ratio

0.36

Quick ratio

0.24

Net debt/EBITDA

-0.15

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-194.5%

Return on equity

N/A

Return on invested capital

N/A

Return on capital employed

N/A

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

NRXP stock price

How has the NRX Pharmaceuticals stock price performed over time

Intraday

-5.5%

1 week

-34.39%

1 month

-58.8%

1 year

-68.06%

YTD

-55.22%

QTD

-56.35%

Financial performance

How have NRX Pharmaceuticals's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$27.84M

Net income

-$30.15M

Gross margin

N/A

Net margin

N/A

The operating income has grown by 37% YoY and by 16% from the previous quarter

NRX Pharmaceuticals's net income has increased by 24% YoY and by 16% from the previous quarter

Growth

What is NRX Pharmaceuticals's growth rate over time

Valuation

What is NRX Pharmaceuticals stock price valuation

P/E

N/A

P/B

N/A

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

NRXP's EPS is up by 33% year-on-year and by 20% since the previous quarter

The company's equity has shrunk by 89% QoQ

Efficiency

How efficient is NRX Pharmaceuticals business performance

NRX Pharmaceuticals's ROA has plunged by 55% YoY and by 9% from the previous quarter

Dividends

What is NRXP's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for NRXP.

Financial health

How did NRX Pharmaceuticals financials performed over time

The total assets is 62% less than the total liabilities

NRX Pharmaceuticals's quick ratio has plunged by 81% YoY and by 48% from the previous quarter

NRX Pharmaceuticals's current ratio has plunged by 78% YoY and by 47% from the previous quarter

NRX Pharmaceuticals's debt is 178% more than its equity

The debt to equity has plunged by 155% YoY but it has soared by 52% from the previous quarter

The company's equity has shrunk by 89% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.